Moayyedi P, Leontiadis GI. The risks of PPI therapy. Nat Rev Gastroenterol Hepatol 2012;9:132–139.
Garcia Rodriguez LA, Lin KJ, Hernandez-Diaz S et al. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 2011;123:1108–1115.
Ray WA, Murray KT, Griffin MR et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010;152:337–345.
Bhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909–1917.
Scheiman JM, Devereaux PJ, Herlitz J et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart 2011;97:797–802.
Moukarbel GV, Bhatt DL. Antiplatelet therapy and proton pump inhibition: clinician update. Circulation 2012;125:375–380.
Levine GN, Bates ER, Bittl JA et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 2016;134:e123–e155.
Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol 2012;107:345–360.
Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008;52:1038–1039.
Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937–944.
Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713–718.
Kreutz RP, Stanek EJ, Aubert R et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy 2010;30:787–796.
Huang CC, Chen YC, Leu HB et al. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol 2010;105:1705–1709.
Stockl KM, Le L, Zakharyan A et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 2010;170:704–710.
van Boxel OS, van Oijen MG, Hagenaars MP et al. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol 2010;105:2430–2436.
Munoz-Torrero JF, Escudero D, Suarez C et al. Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry. J Cardiovasc Pharmacol 2011;57:13–19.
Charlot M, Grove EL, Hansen PR et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011;342:d2690.
Burkard T, Kaiser CA, Brunner-La Rocca H et al. Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial. J Intern Med 2012;271:257–263.
Ortolani P, Marino M, Marzocchi A et al. One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study. J Cardiovasc Med (Hagerstown) 2012;13:783–789.
Goodman SG, Clare R, Pieper KS et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation 2012;125:978–986.
Bhurke SM, Martin BC, Li C et al. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy 2012;32:809–818.
Leonard CE, Bilker WB, Brensinger CM et al. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors. Stroke 2015;46:722–731.
Charlot M, Ahlehoff O, Norgaard ML et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 2010;153:378–386.
Valkhoff VE, t Jong GW, Van Soest EM et al. Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther 2011;33:77–88.
Shih CJ, Chen YT, Ou SM et al. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol 2014;177:292–297.
Shah NH, LePendu P, Bauer-Mehren A et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS ONE 2015;10:e0124653.
Juurlink DN, Gomes T, Mamdani MM et al. The safety of proton pump inhibitors and clopidogrel in patients after stroke. Stroke 2011;42:128–132.
Cheng CL, Kao YH, Lin SJ et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011;20:236–242.
Ray WA, Murray KT, Hall K et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881–1890.
Dunn SP, Steinhubl SR, Bauer D et al. Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. J Am Heart Assoc 2013;2:e004564.
O'Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989–997.
Simon T, Steg PG, Gilard M et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation 2011;123:474–482.
Turkiewicz A, Vicente RP, Ohlsson H et al. Revising the link between proton-pump inhibitors and risk of acute myocardial infarction-a case-crossover analysis. Eur J Clin Pharmacol 2015;71:125–129.
Tantry US, Kereiakes DJ, Gurbel PA. Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. JACC Cardiovasc Interv 2011;4:365–380.
Ghebremariam YT, LePendu P, Lee JC et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 2013;128:845–853.
Ghebremariam YT, Cooke JP, Khan F et al. Proton pump inhibitors and vascular function: a prospective cross-over pilot study. Vasc Med 2015;20:309–316.
Wu CS, Wang SC, Cheng YC et al. Association of cerebrovascular events with antidepressant use: a case-crossover study. Am J Psychiatry 2011;168:511–521.
Wang YP, Chen YT, Tsai CF et al. Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Am J Psychiatry 2014;171:54–61.
Wu HH, Chen YT, Shih CJ et al. Association between recent use of proton pump inhibitors and nontyphoid salmonellosis: a nested case-control study. Clin Infect Dis 2014;59:1554–1558.
Shih CJ, Chu H, Chao PW et al. Long-term clinical outcome of major adverse cardiac events in survivors of infective endocarditis: a nationwide population-based study. Circulation 2014;130:1684–1691.
Shih CJ, Ou SM, Chao PW et al. Risks of death and stroke in patients undergoing hemodialysis with new-onset atrial fibrillation: a competing-risk analysis of a nationwide cohort. Circulation 2016;133:265–272.
Siller-Matula JM, Jilma B, Schror K et al. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 2010;8:2624–2641.